Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ferriprotoporphyrin IX (heme) is a vital metabolic byproduct and therapeutic target located within the acidic food vacuole of the malaria parasite Plasmodium falciparum (Sigala & Goldberg, 2014). During the parasite's intraerythrocytic stage, it digests host hemoglobin to obtain amino acids, a process that releases toxic, redox-active free heme (Sullivan, 2002). To prevent cellular damage, the parasite detoxifies this heme by sequestering it into an insoluble crystalline polymer called hemozoin (Egan, 2008). Antimalarial drugs, most notably the 4-aminoquinolines like chloroquine, target this pathway by binding to the heme monomers or the growing faces of hemozoin crystals (Hempelmann, 2007). This binding inhibits further crystallization, leading to an accumulation of toxic heme-drug complexes that cause membrane lipid peroxidation and parasite death (Coronado et al., 2014). Consequently, the disruption of heme detoxification remains one of the most successful strategies in antimalarial chemotherapy.
Inhibition of hemozoin biocrystallization and formation of toxic heme-drug complexes.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ferriprotoporphyrin IX (Fe(III)PPIX) (Fe(III)PPIX).